Tango Therapeutics Inc Cash Flow-to-Debt Ratio
Tango Therapeutics Inc cash flow-to-debt ratio. Tango Therapeutics Inc (TNGX) has a Cash Flow-to-Debt Ratio of -0.79x as of June 2026, meaning its operating cash flow of $-38.87 Million could theoretically repay -1% of its total liabilities ($49.35 Million) in one year. Check Tango Therapeutics Inc (TNGX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tango Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Tango Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Tango Therapeutics Inc across 7 annual periods. Check TNGX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Tango Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Tango Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Tango Therapeutics Inc. For the full cash flow conversion analysis, see TNGX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.64x | $-138.89 Million | $52.51 Million | ▼ -135.3% |
| 2024 | -1.12x | $-131.50 Million | $116.97 Million | ▼ -42.4% |
| 2023 | -0.79x | $-117.98 Million | $149.46 Million | ▼ -35.3% |
| 2022 | -0.58x | $-109.08 Million | $186.99 Million | ▼ -52.3% |
| 2021 | -0.38x | $-59.53 Million | $155.41 Million | ▼ -192.2% |
| 2020 | 0.42x | $70.07 Million | $168.65 Million | ▲ +180.2% |
| 2019 | -0.52x | $-24.80 Million | $47.86 Million | — |